BLUE * Overzicht aandelen bluebird bio, Inc., een biotechnologiebedrijf, onderzoekt, ontwikkelt en verkoopt gentherapieën voor genezende ernstige genetische ziekten in de Verenigde Staten. Meer informatie
Beloningen Risicoanalyse + 1 meer risico
Alle risicocontroles bekijken Leg je gedachten, links en bedrijfsverhaal vast
bluebird bio, Inc. Concurrenten Prijsgeschiedenis en prestaties
Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor bluebird bio Historische aandelenkoersen Huidige aandelenkoers US$186.96 52 Week Hoogtepunt US$500.00 52 Week Laag US$180.00 Bèta 0.73 1 maand verandering -6.52% 3 maanden verandering -6.52% 1 Jaar Verandering n/a 3 jaar verandering -95.55% 5 jaar verandering -99.33% Verandering sinds IPO -99.60%
Recent nieuws en updates
Insufficient new directors Dec 11 Bluebird Bio, Inc. Announces Updated Data from Patients with Beta-Thalassemia Who Require Regular Blood Transfusions Treated with Betibeglogene Autotemcel (Beti-Cel, Approved Commercially as ZYNTEGL) in Clinical Studies
Third quarter 2024 earnings released: US$0.31 loss per share (vs US$0.80 loss in 3Q 2023) Nov 16
New major risk - Revenue and earnings growth Nov 15
bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition Nov 05
bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1) Oct 05 Meer updates bekijken
Insufficient new directors Dec 11 Bluebird Bio, Inc. Announces Updated Data from Patients with Beta-Thalassemia Who Require Regular Blood Transfusions Treated with Betibeglogene Autotemcel (Beti-Cel, Approved Commercially as ZYNTEGL) in Clinical Studies
Third quarter 2024 earnings released: US$0.31 loss per share (vs US$0.80 loss in 3Q 2023) Nov 16
New major risk - Revenue and earnings growth Nov 15
bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition Nov 05
bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1) Oct 05
bluebird bio, Inc., Annual General Meeting, Nov 06, 2024 Sep 19
bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1) Aug 25 bluebird bio, Inc. Provides Revenue Guidance for the Third and Fourth Quarter of 2024
bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024 May 30 bluebird bio, Inc. announced delayed 10-Q filing May 17
Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy May 07
Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc Mar 29 bluebird bio, Inc. announced delayed annual 10-K filing Mar 27
Chief Medical Officer recently sold Mex$176k worth of stock Mar 10
Chief Medical Officer recently sold Mex$176k worth of stock Mar 08 bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million. Dec 21
bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million. Dec 20
bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $150 million. Dec 19
Bluebird Bio Inc. Presents Long-Term Data At Ash Support Beti-Ccel as A Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusion Independence and Normal or Near- Normal- Normal- Normal-Normal Adult Hb Levels Bluebird Bio Details Plans for the Commercial Launch of Lyfgenia(Tm) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and A History of Vaso-Occlusive Events
Bluebird Bio, Inc. to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology Annual Meeting and Exposition Nov 03
bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 25
bluebird bio, Inc. Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease (Scd) 12 Years and Older with a History of Vaso-Occlusive Events Jun 22
Less than half of directors are independent Apr 12
Full year 2022 earnings released: US$3.39 loss per share (vs US$8.17 loss in FY 2021) Mar 31
Less than half of directors are independent Mar 30
Less than half of directors are independent Feb 17
bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer Jan 04
U.S. Food and Drug Administration Lifts Partial Clinical Hold for bluebird bio, Inc.’s Sickle Cell Disease Studies for Patients Under the Age of 18 Dec 20
Less than half of directors are independent Dec 16
Bluebird Bio, Inc. Presents New and Updated Data At the 64Th American Society of Hematology Annual Meeting and Exposition Dec 13
An unknown buyer entered into a definitive agreement to acquire SKYSONA & ZYNTEGLO of bluebird bio, Inc. (NasdaqGS:BLUE) for approximately $100 million. Dec 02 bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer
Less than half of directors are independent Oct 17 bluebird bio, Inc. Announces Executive Changes Effective October 14, 2022
bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD) Sep 17 bluebird bio, Inc. Announces Executive Changes
Treasurer recently sold Mex$1.6m worth of stock Aug 25
bluebird bio, Inc. Announces FDA Approval of Zynteglo®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions Aug 18
President recently sold Mex$1.9m worth of stock Aug 10
Second quarter 2022 earnings released: US$1.36 loss per share (vs US$2.31 loss in 2Q 2021) Aug 07
bluebird bio, Inc. Appoints Tom Klima as Chief Commercial & Operating Officer, Effective August 8, 2022 Aug 06
Chief Regulatory Officer recently sold Mex$140k worth of stock Jul 15
Less than half of directors are independent Jul 05
bluebird bio, Inc. Announces That the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee Recommends Approval of elivaldogene autotemcel (eli-cel) for the Treatment of Early Active Cerebral Adrenoleukodystrophy Jun 11
FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy Jun 10
Chief Commercial Officer recently sold Mex$226k worth of stock Jun 08
Less than half of directors are independent Jun 01
bluebird bio, Inc., Annual General Meeting, Jun 22, 2022 May 03 Bluebird Bio, Inc. Announces Executive Changes
bluebird bio, Inc. appoints Charlotte Jones-Burton as Class I director, effective March 7, 2022 Mar 06 bluebird bio, Inc. announced delayed annual 10-K filing Mar 03
Less than half of directors are independent Mar 01
bluebird bio, Inc. Announces Resignation of Jessica Whitten as Chief Accounting Officer and Principal Accounting Officer Feb 05
Less than half of directors are independent Feb 04
bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD) Jan 19
Insider recently sold Mex$80k worth of stock Jan 15
bluebird bio, Inc. to Launch Both beti-cel and eli-cel for Patients in the U.S. in Mid-2022 Jan 12
Insider recently sold Mex$637k worth of stock Jan 08
Less than half of directors are independent Dec 29
bluebird bio, Inc. Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program Dec 21
bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) in Patients Without a Matched Sibling Donor Dec 19
CEO & Director recently sold Mex$179k worth of stock Dec 14
bluebird bio, Inc. Announces Updated Results from its Phase 1/2 HGB-206 Study of Lovotibeglogene Autotemcel Gene Therapy Dec 13
New Data At ASH21, Published in Nejm Further Demonstrate Beti-Cel as A Potentially Curative One-Time Gene Therapy for ß-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Ti and Normal or Near-Normal Adult Hb Levels Dec 12
Independent Director Wendy Dixon has left the company Nov 29
Independent Director Wendy Dixon has left the company Nov 29
Independent Director Wendy Dixon has left the company Nov 29
Independent Director Wendy Dixon has left the company Nov 29
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28
Independent Director Wendy Dixon has left the company Nov 28 Rendement voor aandeelhouders BLUE * MX Biotechs MX Markt 7D 0% 0% 0% 1Y n/a 0% 0%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe BLUE * presteerde ten opzichte van de MX Biotechs.
Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe BLUE * presteerde ten opzichte van de MX markt.
Prijsvolatiliteit Is BLUE *'s price volatile compared to industry and market? BLUE * volatility BLUE * Average Weekly Movement n/a Biotechs Industry Average Movement 0% Market Average Movement 0% 10% most volatile stocks in MX Market 0% 10% least volatile stocks in MX Market 0%
Stabiele aandelenkoers: De aandelenkoers van BLUE * is de afgelopen 3 maanden volatiel geweest in vergelijking met de MX markt.
Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van BLUE * in het afgelopen jaar te bepalen.
Over het bedrijf bluebird bio, Inc., een biotechnologiebedrijf, onderzoekt, ontwikkelt en commercialiseert gentherapieën voor curatieve ernstige genetische ziekten in de Verenigde Staten. De productkandidaten van het bedrijf voor ernstige genetische ziekten omvatten ZYNTEGLO (betibeglogene autotemcel) voor de behandeling van transfusie-afhankelijke ß-thalassemie; lovotibeglogene autotemcel voor de behandeling van sikkelcelziekte (SCD); en SKYSONA (elivaldogene autotemcel) voor de behandeling van cerebrale adrenoleukodystrofie. Haar klinische ontwikkelingsprogramma's omvatten HGB-205, HGB-206 en HGB-210 om de veiligheid en doeltreffendheid van lovo-cel te evalueren bij de behandeling van patiënten met SCD; en HGB-204, HGB-205, HGB-207 en HGB-212 om de veiligheid en doeltreffendheid van beti-cel te evalueren bij de behandeling van patiënten met ß-thalassemie.
Meer tonen bluebird bio, Inc. Samenvatting Hoe verhouden de winst en inkomsten van bluebird bio zich tot de beurswaarde? BLUE * fundamentele statistieken Marktkapitalisatie Mex$1.84b Inkomsten(TTM ) -Mex$6.05b Inkomsten(TTM ) Mex$1.10b
1.7x P/S-verhouding
-0.3x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) BLUE * resultatenrekening (TTM ) Inkomsten US$53.12m Kosten van inkomsten US$78.78m Brutowinst -US$25.66m Overige uitgaven US$267.16m Inkomsten -US$292.82m
Laatst gerapporteerde inkomsten
Sep 30, 2024
Volgende inkomensdatum
n.v.t.
Winst per aandeel (EPS) -30.12 Brutomarge -48.31% Nettowinstmarge -551.25% Schuld/Eigen Vermogen Verhouding -1,394.4%
Hoe presteerde BLUE * op de lange termijn?
Bekijk historische prestaties en vergelijking
Bedrijfsanalyse en status van financiële gegevens Gegevens Laatst bijgewerkt (UTC-tijd) Bedrijfsanalyse 2025/01/05 06:01 Aandelenkoers aan het einde van de dag 2024/12/19 00:00 Inkomsten 2024/09/30 Jaarlijkse inkomsten 2023/12/31
Gegevensbronnen De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC . De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
Pakket Gegevens Tijdframe Voorbeeld Amerikaanse bron * Financiële gegevens bedrijf 10 jaar Resultatenrekening Kasstroomoverzicht Balans Consensus schattingen analisten +3 jaar Financiële prognoses Koersdoelen analisten Marktprijzen 30 jaar Aandelenprijzen Dividenden, splitsingen en acties Eigendom 10 jaar Top aandeelhouders Handel met voorkennis Beheer 10 jaar Leiderschapsteam Raad van bestuur Belangrijkste ontwikkelingen 10 jaar
* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.
Analysemodel en Snowflake Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina . We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube .
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .
Bronnen van analisten bluebird bio, Inc. wordt gevolgd door 33 analisten. 9 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
Analist Instelling Jack Allen Baird Huidong Wang Barclays Zhiqiang Shu Berenberg
Toon 30 meer analisten 
